Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2026 Oct 27.
Published before final editing as: Am J Med Genet A. 2026 Aug 21:10.1002/ajmg.a.70291. doi: 10.1002/ajmg.a.70291

Prenatal Referrals for Differences of Sex Development: Genetic Diagnoses and Clinical Outcomes at a Tertiary Fetal Care Center

Lylach Haizler-Cohen 1,2,3, Nicole R Legro 4, Anne Eckert 1, Sonja A Duncan 5, Tucker L C Pyle 1,5
PMCID: PMC13709213  NIHMSID: NIHMS2213705  PMID: 42629993

Abstract

The objective of this study was to characterize prenatal referrals for differences of sex development (DSD) and associated genetic diagnoses and clinical outcomes at a tertiary fetal care center. We conducted a retrospective review of prenatal referrals to our center for concern of fetal DSD. Referral indications included: sex chromosome DSD (Group 1), atypical genitalia (Group 2), and discordance between fetal chromosomal and phenotypic sex (Group 3). Maternal demographics, fetal imaging findings, genetic testing results, pregnancy outcome, postnatal genital phenotype, and endocrine evaluations were recorded. Between 2012 and 2024, 255 patients were referred: 161 for sex chromosome DSD, 85 for atypical genitalia, and 9 for fetal sex discordance. Of fetuses in Groups 2 and 3 (n = 94), cytogenetic abnormalities were identified in 15 fetuses (5 chromosome aneuploidies, 1 sex chromosome DSD, and 9 copy number variants), most with multiple congenital anomalies. Six single-gene disorders were diagnosed: two congenital adrenal hyperplasia, two androgen insensitivity syndrome, one 17-beta hydroxysteroid dehydrogenase deficiency, and one NR5A1-related testicular DSD. The overall diagnostic yield of genetic testing was 22% (21/94). Of 64 fetuses with postnatal data, 61% were 46,XY DSD, 16% were 46,XX DSD, and 22% were false positive. Cytogenetic abnormalities and single-gene disorders are implicated in prenatal presentations of DSD, some of which may have multisystemic findings or medically important interventions after birth.

Keywords: atypical genitalia, differences of sex development, fetal sex discordance, prenatal, ultrasound

1 |. Introduction

The early prediction of fetal sex, popularly known as the “gender reveal” blood test, has become a routine component of modern prenatal care. The widespread adoption of cell-free fetal DNA (cffDNA) screening, together with advances in fetal ultrasonography, has increased the detection of sex chromosome aneuploidies, atypical fetal genitalia, and discrepancies between fetal chromosomal sex on cffDNA and phenotypic sex on ultrasound. In fact, it is estimated that 1 in every 1500–2000 pregnancies is affected by fetal sex discordant results (Richardson et al. 2017). As a result, prenatal referrals to specialized pediatric and fetal care centers for suspected differences of sex development (DSD) have risen substantially. DSD represent a heterogeneous group of conditions involving variations in chromosomal, gonadal, or anatomic sex development (Hughes et al. 2006). Prenatal and postnatal algorithms for the management of suspected DSD are well established and aim to clarify diagnosis, guide parental counseling and decision-making, plan for postnatal management, and evaluate recurrence risk in future pregnancies (Hughes et al. 2006; Weidler et al. 2024; Chitty et al. 2012; van Bever et al. 2023).

The phenotypic spectrum of DSD is broad and heterogeneous ranging from syndromic presentations with multiple congenital anomalies (e.g., chromosomal aneuploidies or copy number variants [CNV]), to atypical or discordant genitalia at birth (e.g., congenital adrenal hyperplasia or androgen insensitivity syndrome), later presentation with amenorrhea or infertility (e.g., some patients with Turner syndrome), or an entirely asymptomatic course (Hughes et al. 2006; Brain et al. 2010). Traditionally, DSD are classified into three categories: (1) sex chromosome DSD, (2) 46,XX DSD, and (3) 46,XY DSD (Hughes et al. 2006). The 46,XX and 46,XY categories are further classified into conditions arising from gonadal dysgenesis, disorders of hormonal synthesis or action, syndromic presentations, and isolated anatomic variants, such as hypospadias or cloacal malformation, for which no underlying etiology is identified.

Despite the increasing frequency of prenatal referrals for suspected DSD over the past decade, few large, longitudinal datasets have characterized the full spectrum of referral indications, genetic diagnoses, and clinical outcomes. In this study, we sought to address these gaps by evaluating a large cohort of prenatal DSD referrals to a tertiary fetal care center over a 12-year period. Our objectives were to assess the diagnostic yield of genetic testing and clinical outcomes in this population and to determine the proportion of 46,XX DSD, 46,XY DSD, and referrals ultimately determined to represent false positive concern for DSD.

2 |. Methods

2.1 |. Study Design and Population

This was a retrospective cohort study of all prenatal referrals for suspected DSD evaluated at a tertiary fetal care center between January 2012 and December 2024. All referrals were seen at the Zickler Family Prenatal Pediatrics Institute at Children's National Hospital and referred by maternal fetal medicine specialists in Washington D.C., Maryland, and Virginia.

2.2 |. Editorial Policies and Ethical Considerations

Institutional review board approval was obtained. Informed consent was waived due to the retrospective nature of the study.

2.3 |. Indications for Referral and Clinical Evaluation

Patients were referred for prenatal consultation for a fetal concern of DSD for one of three following indications: (1) Suspected sex chromosome DSD by prenatal genetic screening with cffDNA or confirmed by prenatal diagnostic testing; (2) atypical fetal genitalia detected on prenatal ultrasound (genitalia does not appear completely male or female); and (3) discordance between fetal chromosomal sex on cffDNA and phenotypic sex on fetal ultrasound.

Referrals for suspected or confirmed sex chromosome DSD were seen for a genetics consultation at our center by a pediatric clinical geneticist with expertise in prenatal genetics, and a prenatal genetic counselor. Referrals for atypical genitalia or fetal sex discordance underwent comprehensive evaluation at our center including fetal ultrasound, fetal magnetic resonance imaging (MRI), genetics consultation, and, based on the indication for referral, prenatal consultation with a pediatric subspecialist (e.g., endocrinology, urology, pediatric surgery) or a representative from the multidisciplinary DSD specialty clinic (Positive Reevaluation of Urogenital Differences [PROUD]). The PROUD clinic provides specialized diagnostic, evaluation, and treatment services for children with rare and complex DSD conditions and includes specialists in pediatric urology, adolescent gynecology, pediatric surgery, genetics, endocrinology, psychology, and social work. Patients were also offered to meet with a prenatal mental health specialist via telehealth for additional support. Fetal ultrasound and MRI studies were interpreted by pediatric radiologists with specialized expertise in fetal imaging.

2.4 |. Patient Identification and Eligibility

We retrospectively identified prenatal referrals for DSD evaluation by searching the prenatal electronic health records using the following terms: abnormal genetic screening, abnormal prenatal screening, ambiguous genitalia, atypical genitalia, chromosome abnormality, clitoromegaly, cloacal exstrophy, cloacal malformation, genetic syndrome, hypospadias, Klinefelter syndrome, micropenis, and Turner syndrome. We excluded referrals in which the indication was unrelated to DSD, including abnormal prenatal diagnostic testing results with no relevance to sex development, fetal anomalies not related to the genitalia, parental carrier screening, abnormal second trimester screen results, and pregnancies with insufficient documentation. Eligible pregnancies were categorized into one of three groups based on the aforementioned indications: suspected or confirmed sex chromosome DSD (Group 1), atypical genitalia (Group 2), or fetal sex discordance (Group 3). Referrals for atypical genitalia and fetal sex discordance were further subclassified into isolated cases (i.e., no other extragenital anomalies) and non-isolated cases with additional extragenital anomalies.

2.5 |. Data Collection

The electronic health record was reviewed retrospectively for pregnant patients and their neonates. Data were abstracted from maternal fetal medicine referral records, fetal imaging reports, clinical genetics and subspecialty consultation notes, prenatal and postnatal genetic testing results, and postnatal inpatient and outpatient records. In the atypical genitalia and fetal sex discordance groups, collected variables included maternal demographic characteristics, fetal imaging findings (ultrasound and MRI), pregnancy outcomes (termination of pregnancy, intrauterine fetal demise, live birth, and neonatal death), prenatal and postnatal genetic testing results, and postnatal outcomes (i.e., genital phenotype, additional neonatal phenotypic findings, endocrine evaluations, and sex of rearing). In the sex chromosome DSD group, more limited data was collected including prenatal and postnatal genetic testing results and pregnancy outcome.

Most neonates in the atypical genitalia and fetal sex discordance groups were either transferred to our institution after birth for further workup and treatment, or received outpatient follow-up in the PROUD clinic or relevant pediatric subspecialty service. Postnatal data was unavailable for infants delivered at outside hospitals without transfer or outpatient follow-up at our center. Since our institution does not offer obstetric services, follow-up was limited for pregnancies involving termination of pregnancy or intrauterine fetal demise. In our three-state catchment area, termination of pregnancy is allowed in all stages of pregnancy (Washington D.C. and Maryland) or until late in the second trimester (Virginia).

2.6 |. Genetic Testing Results and Interpretation

For each patient, we collected all available prenatal and postnatal genetic testing results, including noninvasive prenatal testing (cffDNA or maternal serum screening), chromosomal analysis, chromosomal microarray analysis, targeted gene panels, exome or genome sequencing, and biochemical testing. cffDNA was performed in almost all patients as it is widely available and covered by most insurance companies. Chromosomal microarray analysis was performed on the proband with recommendation for parental testing if a CNV was found, but this was not always done. Targeted gene panels were performed on the proband only, with subsequent parental testing if variants of uncertain significance were identified to clarify pathogenicity. Exome and genome sequencing were performed preferentially as duo or trio with parental samples when available. Variants of uncertain significance were reported in exome or genome sequencing only postnatally, as generally accepted. Classification of copy number and sequence variants was based on ACMG guidelines (Riggs et al. 2020; Richards et al. 2015).

Prenatal diagnostic testing was performed via chorionic villus sampling or amniocentesis by the referring maternal fetal medicine provider either before (most cases) or after referral to our center. The decision to pursue diagnostic testing was based on parental preferences and recommendations for testing from the maternal fetal medicine provider and/or our consultation. Chorionic villi and amniotic fluid specimens were sent to outside genetics laboratories per the referring maternal fetal medicine specialist's discretion. At times, after our consultation, additional genetic testing was recommended. This was communicated with the referring maternal fetal medicine provider with the recommendation to add the testing to the stored chorionic villi or amniotic fluid if this was available. Sequencing, via gene panels, exome sequencing or genome sequencing, was commonly recommended for referrals for atypical genitalia and fetal sex discordance, especially if cytogenetic testing was previously performed and negative. After the initial consultation at our center, follow-up genetics consultation was offered if any new positive genetic testing results were obtained. Postnatal genetic testing was sent to our center's in-house genetics laboratory.

2.7 |. Categorization of Fetuses Into 46,XX DSD, 46,XY DSD, and False Positive

For the atypical genitalia and fetal sex discordance groups, we compared genetic testing results with the observed postnatal genital phenotype (when available) or fetal genital phenotype on ultrasound, to determine whether the final diagnosis was consistent with 46,XX DSD, 46,XY DSD, or a false positive concern for DSD. 46,XX DSD and 46,XY DSD categories were further classified into gonadal dysgenesis, hormonal dysfunction, syndromic (chromosomal aneuploidies and CNV), or other (i.e., anatomic genital differences where an underlying genetic or hormonal etiology was not identified). False-positive results were defined as atypical genitalia on ultrasound but typical male or female genitalia at birth, or apparent discordance between cffDNA sex prediction and fetal genital phenotype on ultrasound but concordance between diagnostic testing (either by chorionic villus sampling, amniocentesis or postnatal testing) and postnatal genitalia.

Descriptive statistics were used to summarize demographic, genetic, and clinical outcome data.

3 |. Results

3.1 |. Characteristics of Prenatal Referral for Differences of Sex Development

The flow diagram for identification of prenatal DSD referrals for the study cohort is shown in Figure 1. Using the search terms described earlier, 440 patients were identified. After applying exclusion criteria, 255 prenatal consults for DSD were included in the study. Of those, 161 (63%) were for sex chromosome DSD, 85 (33%) were for atypical genitalia, and 9 (4%) were for fetal sex discordance. 26% of atypical genitalia referrals and 33% of fetal sex discordance referrals were isolated, respectively. Figure 2 shows the prenatal referrals for DSD by year between 2012 and 2024. The number of referrals has gradually increased throughout the study years. The largest increase was for sex chromosome DSD while the referrals for atypical genitalia and fetal sex discordance remained steady.

FIGURE 1 |.

FIGURE 1 |

Flow diagram showing identification, inclusion and exclusion of prenatal referrals for the study cohort.

†Search terms for prenatal referrals identification included: Abnormal genetic screening, abnormal prenatal screening, ambiguous genitalia, atypical genitalia, chromosome abnormality, clitoromegaly, cloacal exstrophy, cloacal malformation, genetic syndrome, hypospadias, Klinefelter syndrome, micropenis, and Turner syndrome.

cffDNA, cell free fetal DNA; DSD, differences of sex development.

FIGURE 2 |.

FIGURE 2 |

Prenatal referrals by year for differences of sex development. Blue indicates prenatal referrals for suspected or confirmed sex chromosome DSD (Group 1), orange indicates prenatal referrals for atypical genitalia (Group 2), and green indicates prenatal referrals for discordance between fetal sex based on cell-free fetal DNA and sonographic appearance of the genitalia (Group 3). DSD, difference of sex development.

Characteristics of prenatal referrals for DSD in our center is detailed in Table 1. In Groups 2 and 3, the mean gestational age at referral was lower and the proportion of fetal growth restriction was higher in isolated cases compared to non-isolated cases. Prenatal diagnostic testing was performed in 65%, 41%, and 78% of the sex chromosome DSD, atypical genitalia, and fetal sex discordance groups, respectively. Cytogenetic testing was performed more commonly than sequencing in Groups 2 and 3. Postnatal genetic testing was performed in 55%, 39%, and 33% of these three groups, respectively. When accounting for both prenatal and postnatal testing, sequencing was more commonly performed in the non-isolated groups than the isolated groups. Termination of pregnancy was most common in non-isolated atypical genitalia (22%) and fetal sex discordance (66%) groups. Intrauterine fetal death occurred in four fetuses with sex chromosome DSD and five fetuses with non-isolated atypical genitalia. Neonatal death occurred in three infants with atypical genitalia.

Table 1:

Characteristics of prenatal referrals for differences of sex development

Sex chromosome DSD (Group 1) n=161 Atypical genitalia (Group 2) n=85 Fetal sex discordance (Group 3) n=9

Isolated (n=22) Nonisolated (n=63) Isolated (n=3) Nonisolated (n=6)

Gestational age at referral (mean) N/A 27 weeks 25 weeks 23 weeks 22 weeks

Twin pregnancies 1 1 (5%) 2 (3%) 0 0

Fetal growth restriction N/A 3 (14%) 22 (35%) 0 4 (66%)

Prenatal diagnostic testing† 104 (65%) 6 (27%) 29 (46%) 2 (66%) 5 (83%)
 Karyotype 83 4 16 2 5
 FISH 35 2 14 2 3
 CMA 26 6 25 1 4
 Single gene 0 1 0 0 0
 Gene panel 0 0 7 1 2
 ES/GS 0 1 4 0 1
 Biochemical 0 0 3 0 2

Postnatal genetic testing† 89 (55%) 9 (41%) 26 (41%) 2 (33%) 1 (17%)
 Karyotype 88 5 8 2 0
 FISH 0 1 0 0 0
 CMA 1 2 8 0 0
 Single gene 0 1 2 0 0
 Gene panel 0 2 6 0 0
 ES/GS 0 1 8 0 1
 7-DHC 0 0 1 0 0

Pregnancy outcome
 TOP 19 (12%) 0 14 (22%) 0 4 (66%)
 IUFD 4 (2%) 0 5 (8%) 0 0
 Live birth 133 (83%) 21 (95%) 37 (59%) 3 (100%) 2 (33%)
 Neonatal death 0 1 (5%) 2 (3%) 0 0
 Lost to follow-up 5 (3%) 0 5 (8%) 0 0

Abbreviations: 7-DHC, 7-dehydrocholesterol (biochemical testing for Smith Lemli Opitz syndrome); CMA, chromosomal microarray; ES, exome sequencing; FISH, fluorescent in situ hybridization; GS, genome sequencing; IUFD, intrauterine fetal demise; TOP, termination of pregnancy.

†

Percentage of pregnancies who had at least one genetic test completed, regardless of the type of genetic test.

The types of extragenital anomalies in the atypical genitalia and fetal sex discordance groups are detailed in Figure 3. Multisystem anomalies (n = 41) were the most common followed by soft markers (n = 7) and central nervous systems (n = 6). Spine, urinary, and gastrointestinal anomalies were each present in four fetuses. Soft markers are minor ultrasound findings that do not represent a structural abnormality but indicate an increased risk of an aneuploidy (e.g., echogenic intracardiac foci, short long bones, and hydronephrosis).

FIGURE 3 |.

FIGURE 3 |

Extra-genital abnormalities in referrals for atypical genitalia (Group 2) and fetal sex discordance (group 3). Multisystem abnormalities indicate major fetal structural abnormalities in at least two organ systems. Soft markers are defined as ultrasound findings that do not constitute a major fetal structural abnormality and increase the risk of fetal aneuploidy.

3.2 |. Findings in Sex Chromosome DSD Group

Karyotypic findings in the sex chromosome DSD group with available diagnostic testing (n = 140) are shown in Table 2. Typical sex chromosomes (XX or XY) were identified in 20 fetuses. The most common sex chromosome DSD were Klinefelter syndrome (n = 49), mosaic Turner syndrome (n = 27), 47,XXX (n = 15), 47,XYY (n = 14), and 45,X (n = 10). Mixed gonadal dysgenesis was observed in four fetuses. One fetus with 48,XXXX was identified. From all mosaic Turner fetuses, 45,X/46,XX was the most common followed by 45,X/46,X,r(X).

Table 2:

Karyotypic findings in referrals for sex chromosome DSD (group 1) with available prenatal or postnatal diagnostic testing

Karyotypic finding Frequency (n=140)

45,X 10

Mosaic Turner 27
 45,X/46,XX 13
 45,X/46,X,r(X) 7
 45,X/46,X, del(X)(q23) 4
 46,X,+mar/47,X,+2mar/46,XX 1
 46,X,i(X)(q10)/45,X 1
 46,X, i(Xq10)/47,X,i(Xq10),+i(Xq10)/45,X 1

Mixed gonadal dysgenesis 4
 45,X/46,XY 1
 45,X/46,X,idic(Y)(q11.22)/46,XY 1
 45,X/46,X, psu idic(Y)(q11.22) 2

47,XXX 15

47,XXY 49

47,XYY 14

48,XXXX 1

Normal sex chromosomes (46,XX or 46,XY) 20

3.3 |. Genetic Findings in Atypical Genitalia and Fetal Sex Discordance Groups

Across all pregnancies in these groups (n = 94), a genetic diagnosis was established in 21 fetuses, yielding an overall diagnostic rate of 22.3%. Cytogenetic findings in prenatal referrals for atypical genitalia and fetal sex discordance are detailed in Table 3. Chromosomal aneuploidies were identified in five fetuses with multiple congenital anomalies: triploidy (n = 2), trisomy 13 (n = 2), and mosaic trisomy 22 (n = 1). Mixed gonadal dysgenesis (45,X/46,XY) was identified in one fetus with discordant fetal genitalia. CNV were identified in nine fetuses with multiple congenital anomalies and included: 1q42.11q44 duplication/1q44 deletion, 7p22.3p21.2 duplication/18q22.1q23 deletion (unbalanced translocation), 8p11.21 deletion, 8p23.3p22 deletion, 10p15.3q21.3 duplication/12q24.33 duplication (supernumerary translocation derivative), 13q31.1q34 deletion, 15q26.1q26.3 deletion, 16p11.2 duplication and 22q12.1q13.33 duplication. Of fetuses with cytogenetic findings (n = 15), extragenital anomalies and fetal growth restriction were seen in 14 (93%) and 8 (53%), respectively. Although atypical genitalia have not been reported in association with all identified CNV, all CNV were associated with multiple congenital anomalies overlapping with the fetal phenotype and were therefore considered diagnostic. Of fetuses with cytogenetic findings, six pursued termination of pregnancy, two had an intrauterine fetal demise, and seven had a live birth.

Table 3:

Cytogenetic findings in prenatal referrals for atypical genitalia and fetal sex discordance (groups 2 and 3)

Patient number Prenatal and postnatal phenotype Prenatal and postnatal genetic testing results CNV region and size Clinical significance Outcome
6 Prenatal: Atypical genitalia, Dandy Walker malformation, pontine hypoplasia, agenesis of the corpus callosum, kyphoscoliosis, tethered cord, bilateral cleft lip and palate, proboscis, small kidneys, bilateral rocker bottom feet, borderline thickened nuchal cord, cardiomegaly with pericardial effusion Prenatal:
- Quad screen low risk
- Amniocentesis:
Karyotype 47,XY,+mar
FISH normal male
CMA: Arr [hg19]
10p15.3q21.3(100,026–70,580,859)x3
12q24.33(131,679,076–133,777,902)x3
- 10p15.3q21.3 duplication (70.58 Mb)
- 12q24.33 duplication (2.1 Mb)
Pathogenic

Large gene content predicted to cause multiple congenital anomalies.

Supernumerary translocation derivative, 3:1 meiotic segregation
TOP
24 Prenatal: Atypical genitalia, FGR, Chiari II malformation, spinal dysraphism, meningocele, tethered cord, small nasal bone, possible VSD, mild right hydronephrosis, bilateral clubfeet, syndactyly of left toes, small omphalocele, thickened placenta Prenatal:
- cffDNA low risk male
- First trimester screen low risk
- Amniocentesis:
Karyotype 69,XXY
Triploidy TOP
26 Prenatal: Atypical genitalia, Dandy Walker malformation, tethered cord, grade 3 hydronephrosis, bulbous tufts of fingers, small right fifth toe.

Father of baby has balanced translocation 46,XY,t(7;18)(p21.2;q22.1
Prenatal:
- First trimester screen low risk
- CVS:
CMA female: Arr[hg19]
18q22.1q23(64,150,704–78,014,123)x1
7p22.3p21.2 (43,360–16,161,154)x3 paternal
14q21.2q21.3(47,106,174–48,644076)X1, de novo
- 18q22.1q23 terminal deletion (13.9 Mb)
- 7p22.3p21.2 terminal duplication (16.1 Mb)
- 14q21.2q21.3 interstitial deletion (1.5 Mb)
Unbalanced derivative 18, t(7;18)(p21.2;q22.1)
Pathogenic
Large gene content expected to cause multiple fetal anomalies

Interstitial deletion 14q21.2q21.3
Includes MDGA2, no clinically established phenotype.
TOP
34 Prenatal: Clitoromegaly, FGR, mild ventriculomegaly, prominent cupped ears bilaterally, polyhydramnios, marginal cord insertion

Postnatal: Normal female genitalia, precocious puberty at age 5
cffDNA low risk female

Postnatal:
CMA female
arr[hg19] 1q42.11q44(224,105,294–248,031,766)x3
arr[hg19] 1q44(248,036,351–249,224,684)x1
unknown inheritance
- 1q42.11q44 duplication (23.9 Mb)
- 1q44 deletion (1.2Mb)
1q42.11q44 duplication: pathogenic. Associated with macrocephaly, prominent forehead, microretrognathia,
developmental delay, intellectual disability, and congenital heart defects.

1q44 deletion: pathogenic. Associated with microcephaly, seizures, agenesis of the corpus callosum, polydactyly,
developmental delay, and congenital heart defects.
Live birth
45 Prenatal: Atypical genitalia, small cerebral measurements, suspected Blake's pouch cyst, short long bones, peripheral liver calcifications, polyhydramnios

Postnatal: Penoscrotal hypospadias, developmental delay, short stature, vermian hypoplasia, sacral dimple, conus medullaris at L2–3
Prenatal:
- cffDNA low risk female
- First trimester screen high risk for trisomy 21 and trisomy 18
- Amniocentesis:
Kartyotype 46,XY
FISH normal male
CMA negative
Skeletal dysplasia and DSD panels negative
DHC negative

Postnatal:
- CMA Arr[GRCh37]
16p11.2(29,654,588–30,177,224)x3 paternal inheritance
16p11.2 duplication (523 Kb) Pathogenic
Associatd with developmental delay, intellectual disability and autism. Incomplete penetrance and variable expressivity.
Live birth
52 Prenatal: Small phallus, hypoplastic corpus callosum, vermis hypoplasia, rhomboencephalosynapsis, micrognathia, rocker bottom feet, several EIF

Postnatal: micropenis, bilateral polydactyly, bicuspid aortic VSD, patent foramen ovale, PDA
Prenatal:
- cffDNA increased risk trisomy 13
- First trimester screen low risk
Postnatal:
- Karyotype 47,XY, +13
Trisomy 13 Live birth
54 Prenatal: Downturned curved phallus, bifid scrotum, undescended testes, FGR, microcephaly, small cerebral measurements, mild vermian hypoplasia, Prenatal:
- Second trimester screen normal
- FISH normal female
- CMA Arr[hg19]22q12.1q13.33(28,486,999–51,197,838)x3, unknown inheritance
22q12.1q13.33 terminal duplication (22.7Mb) Pathogenic
Associated with dysmorphic features, intellectual disability, microcephaly and developmental delays.
IUFD after placental abruption
56 Prenatal: Small phallus, no scrotum, severe FGR, microphthalmia, hypoplastic nasal bone,
TOF
Prenatal:
- cffDNA high risk for triploidy, trisomy 18, and trisomy 13
- cffDNA Genome: low fetal fraction, no result
- Amniocentesis:
Karyotype 69,XXY
FISH triploidy 69,XXY
CMA triploidy male 69,XXY
Triploidy IUFD 24 weeks
60 Prenatal: Bulbous phallus, CDH, pulmonary hypoplasia, hypoplastic right ventricle, pulmonary atresia, tricuspid stenosis, VSD, hypoplastic corpus callosum

Postnatal: Hypospadias, chordee, macrodactyly
cffDNA low risk male

Postnatal:
ES with CNV analysis:
Arr[GRCh37] 8p23.3p22(190, 895–14,095,189)x1, de novo
8p23.3p22 terminal deletion (13.9 Mb) Pathogenic
Involves 81 genes including GATA4.
Associated with developmental delay, intellectual disability, multiple congenital anomalies, dysmorphic features, and microcephaly.
Live birth
61 Prenatal: Small penis, one hemiscrotum, lobar HPS, hypoplastic brainstem and cerebellum, TOF, persistent LSVC, left hand polydactyly, left rocker bottom foot, syndactyly right 2nd and 3rd toes, midface hypoplasia, left sided cleft lip, hypotelorism, FGR Prenatal:
- cffDNA low risk male
- Amniocentesis:
CMA male fetus
arr[hg19]
13q31.1q34(85,819,366–115,107,733)x1, de novo

Postnatal:
- CMA 13q31.1q34 del, de novo
13q31.1q34 terminal deletion (29.3 Mb) Pathogenic
Deletion of numerous genes associated with congenital anomalies, intellectual disability, developmental and growth delays and dysmorphic features.
Live birth
67 Prenatal: Short phallus, increased nuchal translucency in first trimester Prenatal:
- cffDNA low risk male
- CVS:
Karyotype 46,XY
Noonan panel negative
ES with CNV analysis:
Arr[hg19] 8p11.21 (41,785,496–41,792,744)x1, unknown inheritance
8p11.21 deletion (7.25 Kb) Likely pathogenic
Deletion includes KAT6A gene. Associated with developmental delay, intellectual disability, and distinct facial features.
TOP
69 Prenatal: Micropenis, FGR, abnormal vermis, hypoplastic corpus callosum, CDH, dextrocardia, hypoplastic nasal bone, bilaterally echogenic kidneys, dorsiflexion of feet bilaterally, absent meconium, spinal cord tethering L3-L4, SUA Prenatal:
- cffDNA low risk male
- Amniocentesis:
Karyotype 46,XY,del(15)(q26.1)
CMA male
Arr[hg19]15q26.1q26.3(89,630,407–101,622,342)x1, unknown inheritance.
15q26.1q26.3 deletion (12 Mb) Pathogenic
Continuous gene deletion including many coding genes. Associated with prenatal and postnatal growth retardation, microcephaly, developmental delay, congenital heart disease.
TOP
75 Prenatal: Cloacal malformation, absent bladder, Dandy walker malformation, FGR, hemivertebra in thoracolumbar spine, tethered cord, echogenic bowel, mild right hydronephrosis, SUA Prenatal:
- cffDNA low risk female

Postnatal:
- Karyotype 47,XX, +13
Trisomy 13 Live birth
89 Prenatal: Female genitalia, FGR, atrioventricular canal, prominent liver, absent right kidney, hypocoiled cord Prenatal:
- cffDNA low risk male
- Amniocentesis:
Karyotype 47,XY,+22[3]/46,XY[17]
Mosaic trisomy 22 TOP
90 Prenatal: female genitalia

Postnatal: female genitalia
Prenatal:
- cffDNA low risk male
- Amniocentesis:
Karyotype 45,X [32]/46,XY[4]
FISH 45,X (83%)/46XY (17%)

Postnatal:
- Karyotype 45,X[24]/46, XY [26]
Mixed gonadal dysgenesis Live birth

Abbreviations: 7-DHC, 7-dehydrocholesterol; CDH, congenital diaphragmatic hernia; cffDNA, cell free fetal DNA; CMA, chromosomal microarray; CNV, copy number variant; CVS, chorionic villus sampling; EIF, echogenic intracardiac focus; FGR, fetal growth restriction; FISH, fluorescent in situ hybridization; IUFD, intrauterine fetal demise; LSVC, left superior vena cava; SUA, single umbilical artery; VSD, ventricular septal defect; TOF, tetralogy of Fallot; TOP, termination of pregnancy

Single-gene disorders in prenatal referrals for atypical genitalia and fetal sex discordance are detailed in Table 4. Two virilized 46,XX neonates were diagnosed with CYP21A2-congenital adrenal hyperplasia. Two 46,XY neonates with female genitalia were diagnosed with hemizygous AR variants causing androgen insensitivity syndrome. One undervirilized 46,XY neonate was diagnosed with 17-beta hydroxysteroid dehydrogenase deficiency related to biallelic HSD17B3 pathogenic variants. One 46,XX neonate was diagnosed with testicular DSD secondary to a heterozygous NR5A1 pathogenic variant. All pregnancies with single gene disorders were isolated (no extragenital anomalies) and resulted in live births.

Table 4:

Single gene disorders in prenatal referrals for atypical genitalia and fetal sex discordance (groups 2 and 3)

Patient number Prenatal and postnatal phenotype Prenatal and postnatal genetic testing results OMIM ACMG criteria and interpretation Outcome
16 Prenatal: “Tulip like” appearance of genitalia, lateral folds and enlarged central protuberance, possible visualization of uterus.

Postnatal: Clitoromegaly, near complete fusion of labial folds, single genital orifice.
Prenatal:
- cffDNA low risk female

Postnatal:
- Karyotype 46,XX
- FISH normal female
- DSD panel: NM_004959.5(NR5A1): Heterozygous, c.274C>T, p.Arg92Trp, unknown inheritance
Testicular DSD (612965) Likely pathogenic
(PS3, PM2, PP3, PP5)
Live birth
17 Prenatal: Enlarged clitoris, prominent adrenal glands

Postnatal: Virilized genitalia, complete fusion of labia, single opening below phallic structure, no palpable gonads
Prenatal:
- cffDNA low risk female
- Amniocentesis:
CMA normal female
Single gene testing: NM_000500.9(CYP21A2): compound heterozygous
CYP21A1P/CYP21A2 chimera 30-Kb deletion, maternal
c.518T>A p.Ile173Asn, paternal
Congenital adrenal hyperplasia (201910) Maternal:
Pathogenic

Paternal:
Pathogenic (PS3, PM2, PM3, PP3, PP5)
Live birth
44 Prenatal: Clitoromegaly, labia majora separate superiorly but are partially fused inferiorly, enlarged adrenals bilaterally, mild left hydronephrosis

Postnatal: Clitoromegaly, rugated and pigmented labia majora
Prenatal:
- cffDNA low risk female

Postnatal:
- Karyotype 46,XX
- Single gene testing: NM_000500.9(CYP21A2): compound heterozygous
c.955C>T p.Gln319Ter, maternal
CYP21A1P/CYP21A2 chimera 30-Kb deletion, paternal
Congenital adrenal hyperplasia (201910) Maternal:
Pathogenic
(PVS1, PS3, PM3)

Paternal:
Pathogenic
Live birth
73 Prenatal: Split hemiscrotum, micropenis or hypospadias

Postnatal: Proximal hypospadias with the urethral meatus at the mid scrotum, chordee, testes descended bilaterally
Prenatal:
- cffDNA low risk male
- Amniocentesis:
Karyotype 46,XY
CMA normal male
GS: NM_000197.2(HSD17B3): compound heterozygote
c.645A>T, p.Glu215Asp, maternal
c.955C>T, p.Arg45Trp, paternal
17-beta hydroxysteroid dehydrogenase deficiency (264300) Maternal:
Pathogenic (PS3, PM3, PM2, PP3, PP5)

Paternal:
Likely pathogenic
(PM2, PM3, PP3, PP4, PP5)
Live birth
87 Prenatal: Female genitalia, no uterus

Postnatal: Normal female genitalia
Prenatal:
- cffDNA low risk male
- Amniocentesis:
Karyotype 46,XY
FISH normal male
CMA normal male
Single gene testing:
SRD5A2: negative
NM_000044.6(AR): hemizygous c.2301delT, p.Asp768Ilefs*21, inheritance unknown
Androgen insensitivity (300068) Pathogenic
(PVS1, PS4, PM2)
Live birth
94 Prenatal: female genitalia

Postnatal: female genitalia
Prenatal:
- cffDNA low risk male

Postnatal:
- Karyotype 46,XY
- FISH normal male
- DSD panel:
NM_000044.6(AR): hemizygous
c.2495 G>A, p.Arg832Gln, inheritance unknown
Androgen insensitivity (300068) Pathogenic
(PS3, PS4, PM2, PP3, PP5)
Live birth

Abbreviations: ACMG, American College of Medical Genetics; cffDNA, cell-free fetal DNA; DSD, differences of sex development; FISH, fluorescent in situ hybridization; GS, genome sequencing; OMIM, online mendelian inheritance in man

Other relevant genetic findings in prenatal referrals for atypical genitalia and fetal sex discordance are detailed in Table S1. Fetal carrier status (one pathogenic variant in an autosomal recessive condition related to DSD) was identified in three pregnancies for the following conditions: 5-alpha reductase deficiency, 17-beta hydroxysteroid dehydrogenase deficiency, and MYH11-related megacystitis-microcolon-intestinal hypoperistalsis syndrome. Variants of uncertain significance related to DSD were identified in three fetuses for the following conditions: Fraser syndrome (n = 2) and short rib thoracic dysplasia (n = 1).

3.4 |. 46,XX and 46,XY DSD Diagnoses in Atypical Genitalia and Fetal Sex Discordance Groups

A comprehensive review of prenatal and postnatal findings for fetuses in the atypical genitalia and fetal sex discordance groups is summarized in Tables S2 and S3. Figure 4 and Table S4 detail the spectrum of DSD diagnoses stratified by availability of postnatal data (i.e., genital phenotype, postnatal genetic testing, and endocrine evaluation).

FIGURE 4 |.

FIGURE 4 |

Classification to 46,XX and 46,XY DSD in the atypical genitalia (Group 2) and fetal sex discordance (Group 3) groups based on availability of postnatal data. Disorders of sex development categorized into gonadal, hormonal, syndromic (chromosomal aneuploidies other than the sex chromosome or copy number variants), and other. AIS, androgen insensitivity syndrome; CAH, congenital adrenal hyperplasia; del, deletion; DSD, differences of sex development; dup, duplication; VACTERL, vertebral, anorectal, cardiac, tracheoesophageal, renal, limb.

†Genetic etiology not found or no genetic testing performed.

Among fetuses with available postnatal data (n = 64), one had a sex chromosome DSD (mixed gonadal dysgenesis, 45,X/46,XY), two had gonadal dysgenesis, six had hormonal dysfunction due to single-gene disorders or endocrine abnormalities, and five had syndromic presentations (two chromosomal aneuploidies and three pathogenic CNV). Thirty-seven fetuses had anatomic genital abnormalities without an identified etiology, and 14 were ultimately determined to represent false positive concerns for DSD. Overall, 61% (39/64) of fetuses were classified as 46,XY DSD, 16% (10/64) as 46,XX DSD, and 22% (14/64) as false positive.

Among fetuses without available postnatal data (n = 30), 9 were syndromic presentations (4 chromosomal aneuploidy and 5 CNV), 2 had cloacal malformations, 13 had multiple congenital anomalies, and 5 were lost to follow-up. In this subgroup, 63% (19/30) were classified as 46,XY DSD, 13% (4/30) as 46,XX DSD, and 17% (5/30) were lost to follow-up.

4 |. Discussion

In this study, we describe a cohort of prenatal referrals for suspected DSD at a tertiary fetal center. We characterized referral indications, detailed prenatal and postnatal phenotypic data, genetic diagnostic results, and clinical outcomes. The most common referral indication was sex chromosome DSD (63%) followed by atypical genitalia (37%) and fetal sex discordance (4%). In the atypical genitalia and fetal sex discordance groups (n = 94), the overall diagnostic yield of genetic testing was 22%, comprising 15 cytogenetic abnormalities and six single-gene disorders. Among fetuses with available postnatal phenotypic data, 46,XY DSD was more common than 46,XX DSD (61% versus 16%), while 22% of referrals were false positive.

Referrals for suspected sex chromosome DSD comprised the majority of our cohort. The most common findings, in decreasing frequency, were 47,XXY, mosaic Turner variants, 47,XXX, 47,XYY, and 45,X. Although Turner syndrome is the most common sex chromosome aneuploidy identified prenatally, its high rates of spontaneous miscarriage and intrauterine fetal demise (Nussbaum et al. 2016), together with the widespread adoption of cffDNA screening, likely explain why Klinefelter syndrome was most frequently observed in our cohort. In contrast, in a pre-cffDNA cohort by Vlatkovic et al. (2014) of 46 sex chromosome DSD detected following invasive diagnostic testing for abnormal first or second trimester ultrasound findings or for advanced maternal age, Turner syndrome was the most common sex chromosome DSD identified. Notably, 14.3% of referrals for sex chromosome DSD in our study had a typical sex chromosome complement on confirmatory diagnostic testing. Our observed false positive rate is lower than reported in screening-based cohorts (Chaime et al. 2025; Witchel et al. 2025) because individuals with reassuring confirmatory diagnostic testing were less likely to be referred to our tertiary center. Referrals for sex chromosome DSD, but not for other indications, increased throughout the study period likely due to increased utilization of cffDNA in prenatal care.

Our findings highlight that cytogenetic abnormalities including aneuploidies and CNV are important contributors to prenatal DSD presentations, especially when presenting with multiple congenital abnormalities. In our cohort, five aneuploidies and nine pathogenic CNV were identified. Nearly all (14/15, 93%) cytogenetic diagnoses occurred alongside extragenital anomalies. Aneuploidies detected in our cohort including triploidy, trisomy 13, and mosaic trisomy 22, are reported in association with atypical genitalia in the literature (Daniel et al. 2001; Trevisan et al. 2024; Springett et al. 2015). In an 11-year study of 115 individuals with polymalformative syndromes and suspected DSD, 14 were identified to have pathogenic CNV involving chromosomes 3, 4, 9, and 11, with some disrupting known DSD-associated genes (Mary et al. 2023). The CNV in our cohort were distributed across multiple chromosomes, emphasizing the genetic heterogeneity of CNV-associated prenatal DSD and suggesting the involvement of additional, yet undiscovered, genes related to genitourinary development. Additional studies have noted CNV detection in fetuses with DSD and additional anomalies (van Bever et al. 2023; Baetens et al. 2014). These data support prioritizing detection of clinically significant CNV when suspected prenatal DSD is accompanied by additional findings concerning for a syndromic presentation, ideally using trio genome sequencing when available (Barseghyan et al. 2018).

In our cohort, single-gene disorders accounted for only 6.4% (6/94) of referrals for atypical genitalia or fetal sex discordance. Diagnoses included two fetuses with congenital adrenal hyperplasia, two fetuses with androgen insensitivity syndrome, one fetus with 17-beta hydroxysteroid dehydrogenase deficiency and one fetus with NR5A1-related testicular DSD. These findings are consistent with single-gene disorders reported in previous prenatal DSD cohorts and highlight that monogenic etiologies underlying prenatal DSD map to well described pathways in sex development (van Bever et al. 2023; Chaime et al. 2025; Ding et al. 2025). Although single-gene disorders made up a relatively small proportion of prenatal DSD, all occurred in fetuses with isolated genital findings, supporting the use of targeted DSD panels or exome/genome sequencing in fetuses with isolated atypical genitalia or fetal sex discordance. Congenital adrenal hyperplasia, diagnosed in two fetuses in our cohort, imparts immediate implications after birth due to the need for electrolyte monitoring and potentially glucocorticoid and mineralocorticoid therapy (Weidler et al. 2024). Additionally, as some single-gene disorders have recurrence risk in future pregnancies, diagnosis allows accurate counseling on reproductive risk in subsequent pregnancies and prenatal diagnostic testing options (Sofer et al. 2020).

When classifying fetuses as 46,XX or 46,XY DSD, we observed a predominance of 46,XY DSD compared to 46,XX DSD (61% vs. 16%) while 22% were determined to be false positive findings. A similar distribution was reported in a previous prenatal cohort of fetuses referred for atypical genitalia or fetal sex discordance, in which 70% were diagnosed with 46,XY DSD, 11% with 46,XX DSD, 10% with uncategorized DSD (including cloacal malformation and prune belly anomaly), and 10% were false positive (Fuchs et al. 2019). This overrepresentation of 46,XY DSD in prenatal cohorts could be related to ascertainment bias as undervirilization of external genitalia in 46,XY fetuses is more readily detected on prenatal ultrasound, and the presence of Y-chromosome material is more easily identified through cffDNA screening (Goncalves et al. 2019; Shear et al. 2023). Whereas, many 46,XX DSD conditions may lack distinctive prenatal imaging features and be less likely to prompt referral. Beyond ascertainment, 46,XY DSD is more common biologically since loss-of function variants in genes related to testicular development and androgen signaling (e.g., SRY) are better tolerated and thus more prevalent than gain-of-function variants observed in 46,XX DSD (e.g., NR5A1) (Gerasimavicius et al. 2022). False-positive results for atypical genitalia and fetal sex discordance may arise from ultrasonographic factors, such as suboptimal visualization of fetal genitalia due to fetal positioning or increased maternal body habitus, limited sonographer experience or inaccuracies in cffDNA sex predictions.

5 |. Strengths

We comprehensively characterized all prenatal referrals for concern for DSD (i.e., sex chromosome DSD, atypical genitalia and fetal sex discordance) rather than focusing on a single indication, providing a broad overview of the spectrum of prenatal DSD. This is a relatively large cohort in a tertiary fetal care center over a 12-year period, enhancing the reliability and generalizability of our findings in a specialized setting. All pregnancies were evaluated by a clinical genetics team, ensuring standardized assessment and genetic counseling. We were able to obtain postnatal follow-up information for most participants. Furthermore, most patients were followed longitudinally in the multidisciplinary PROUD clinic, allowing us to capture comprehensive phenotypic, genetic, and clinical outcomes over time.

6 |. Limitations

Since our center does not provide obstetric services, postnatal follow-up was not available for pregnancies ending in termination of pregnancy, intrauterine fetal demise or who delivered at outside hospitals but did not transfer care or attend outpatient follow-up at our center. This limited our ability to determine a definitive DSD diagnosis and confidently classify fetuses into the 46,XX and 46,XY DSD categories. While cytogenetic testing was performed in the majority of the cohort, sequencing was performed less commonly, possibly underestimating the contribution of single-gene disorders to prenatal DSD. Additionally, prenatal genetic testing was sent by the referring maternal fetal medicine providers to different outside laboratories, resulting in nonuniform variant interpretation. For some fetuses diagnosed with a CNV, parental testing was not performed or results were not available, limiting our ability to assess the pathogenicity of the CNV. Finally, our cohort may have been biased to more severely affected pregnancies as evidenced by the higher rate of non-isolated referrals compared to isolated referrals. This may have resulted in a higher genetic diagnostic yield than would be expected in the general population for indications of atypical genitalia and fetal sex discordance.

7 |. Conclusion

In this large tertiary care cohort over a 12-year period we capture the full spectrum of prenatal DSD referrals. While most referrals are driven by suspected sex chromosome DSD, a substantial proportion of fetuses referred for atypical genitalia or fetal sex discordance harbor clinically significant genetic diagnoses, particularly cytogenetic abnormalities and, less frequently, single-gene disorders. Single-gene disorders should be especially suspected in cases of isolated atypical genitalia or fetal sex discordance. Based on these findings, we recommend that all pregnancies with atypical genitalia or fetal sex discordance be referred to a tertiary fetal care center for comprehensive multidisciplinary evaluation, including detailed fetal imaging, genetic counseling, and consultation with maternal fetal medicine and relevant pediatric subspecialists. Diagnostic genetic testing should be offered in all cases of prenatal DSD, with karyotype and/or chromosomal microarray as the first line test. Reflex testing with targeted gene panels or exome sequencing should be considered when initial testing is nondiagnostic, especially in cases of isolated atypical genitalia or fetal sex discordance. Identifying a genetic diagnosis provides anticipatory guidance to families, guides postnatal management and treatment, and informs recurrence risk in future pregnancies. Furthermore, prenatal evaluation facilitates coordinated postnatal follow-up, ensuring timely access to necessary specialists during infancy and childhood, and helps families navigate the uncertainty associated with a prenatal DSD diagnosis.

Supplementary Material

Supplementary tables

Additional supporting information can be found online in the Supporting Information section. Table S1: Other relevant findings in prenatal referrals for atypical genitalia and fetal sex discordance (Groups 2 and 3). Table S2: All prenatal referrals for atypical fetal genitalia (Group 2). Table S3: All prenatal referrals for fetal sex discordance (Group 3). Table S4: 46,XX and 46,XY diagnoses in the atypical genitalia and fetal sex discordance groups (Groups 2 and 3).

Acknowledgments

The authors have nothing to report.

Funding

Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under the Award Number KL2TR002367. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Footnotes

Conflicts of Interest

The authors declare no conflicts of interest.

Ethics Statement

Ethics approval for this study was obtained from the Children's National Medical Center Institutional Review Board (IRB) on May 24, 2024 (Study ID/Reference Number: STUDY00000858).

Consent

This study was approved with a waiver of informed consent due to the retrospective design and use of existing medical record data. Parent/guardian consent was therefore not required for inclusion.

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

  1. Baetens D, Mladenov W, Delle Chiaie B, et al. 2014. “Extensive Clinical, Hormonal and Genetic Screening in a Large Consecutive Series of 46,XY Neonates and Infants With Atypical Sexual Development.” Orphanet Journal of Rare Diseases 9: 209. 10.1186/S13023-014-0209-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barseghyan H, Délot EC, and Vilain E. 2018. “New Technologies to Uncover the Molecular Basis of Disorders of Sex Development.” Molecular and Cellular Endocrinology 468: 60–69. 10.1016/j.mce.2018.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brain CE, Creighton SM, Mushtaq I, et al. 2010. “Holistic Management of DSD.” Best Practice & Research. Clinical Endocrinology & Metabolism 24, no. 2: 335–354. 10.1016/J.BEEM.2010.01.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chaime AE, Phillip M, Ben-Meir D, and de Vries L. 2025. “During Three Decades Prenatal Diagnoses of Differences in Sex Development Increased and Gonadectomy Rates Declined.” Acta Paediatrica 114, no. 7: 1668–1679. 10.1111/APA.70017. [DOI] [PubMed] [Google Scholar]
  5. Chitty LS, Chatelain P, Wolffenbuttel KP, and Aigrain Y. 2012. “Prenatal Management of Disorders of Sex Development.” Journal of Pediatric Urology 8, no. 6: 576–584. 10.1016/j.jpurol.2012.10.012. [DOI] [PubMed] [Google Scholar]
  6. Daniel A, Wu Z, Bennetts B, et al. 2001. “Karyotype, Phenotype and Parental Origin in 19 Cases of Triploidy.” Prenatal Diagnosis 21, no. 12: 1034–1048. 10.1002/PD.164. [DOI] [PubMed] [Google Scholar]
  7. Ding Q, Hoppman NL, Thorland EC, et al. 2025. “Artifacts, Not Differences in Sex Development, Are the Predominant Cause of Phenotypic Sex Discordance With Prenatal Cell-Free DNA Screening: A Review of 33 Cases.” Prenatal Diagnosis 45, no. 5: 602–607. 10.1002/PD.6793. [DOI] [PubMed] [Google Scholar]
  8. Fuchs F, Borrego P, Amouroux C, et al. 2019. “Prenatal Imaging of Genital Defects: Clinical Spectrum and Predictive Factors for Severe Forms.” BJU International 124, no. 5: 876–882. 10.1111/BJU.14714. [DOI] [PubMed] [Google Scholar]
  9. Gerasimavicius L, Livesey BJ, and Marsh JA. 2022. “Loss-Of-Function, Gain-Of-Function and Dominant-Negative Mutations Have Profoundly Different Effects on Protein Structure.” Nature Communications 13, no. 1: 3895. 10.1038/S41467-022-31686-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Goncalves LF, Hill H, and Bailey S. 2019. “Prenatal and Postnatal Imaging Techniques in the Evaluation of Disorders of Sex Development.” Seminars in Pediatric Surgery 28, no. 5: 150839. 10.1016/j.sempedsurg.2019.150839. [DOI] [PubMed] [Google Scholar]
  11. Hughes IA, Houk C, Ahmed SF, and Lee PA. 2006. “Consensus Statement on Management of Intersex Disorders.” Archives of Disease in Childhood 91, no. 7: 554–563. 10.1136/ADC.2006.098319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mary L, Fradin M, Pasquier L, et al. 2023. “Role of Chromosomal Imbalances in the Pathogenesis of DSD: A Retrospective Analysis of 115 Prenatal Samples.” European Journal of Medical Genetics 66, no. 6: 104748. 10.1016/j.ejmg.2023.104748. [DOI] [PubMed] [Google Scholar]
  13. Nussbaum RL, McInnes RR, and Willard HF. 2016. Thompson & Thompson Genetics in Medicine. 8th ed. Elsevier. [Google Scholar]
  14. Richards S, Aziz N, Bale S, et al. 2015. “Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.” Genetics in Medicine 17, no. 5: 405–424. 10.1038/gim.2015.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Richardson EJ, Scott FP, and McLennan AC. 2017. “Sex Discordance Identification Following Non-Invasive Prenatal Testing.” Prenatal Diagnosis 37, no. 13: 1298–1304. 10.1002/PD.5184. [DOI] [PubMed] [Google Scholar]
  16. Riggs ER, Andersen EF, Cherry AM, et al. 2020. “Technical Standards for the Interpretation and Reporting of Constitutional Copy-Number Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen).” Genetics in Medicine 22, no. 2: 245–257. 10.1038/s41436-019-0686-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Shear MA, Swanson K, Garg R, et al. 2023. “A Systematic Review and Meta-Analysis of Cell-Free DNA Testing for Detection of Fetal Sex Chromosome Aneuploidy.” Prenatal Diagnosis 43, no. 2: 133–143. 10.1002/PD.6298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sofer L, D'Oro A, Rosoklija I, et al. 2020. “Impact of Cell-Free DNA Screening on Parental Knowledge of Fetal Sex and Disorders of Sex Development.” Prenatal Diagnosis 40, no. 11: 1489–1496. 10.1002/PD.5801. [DOI] [PubMed] [Google Scholar]
  19. Springett A, Wellesley D, Greenlees R, et al. 2015. “Congenital Anomalies Associated With Trisomy 18 or Trisomy 13: A Registry-Based Study in 16 European Countries, 2000–2011.” American Journal of Medical Genetics – Seminars in Medical Genetics, Part A 167A, no. 12: 3062–3069. 10.1002/AJMG.A.37355. [DOI] [PubMed] [Google Scholar]
  20. Trevisan V, Meroni A, Leoni C, et al. 2024. “Trisomy 22 Mosaicism From Prenatal to Postnatal Findings: A Case Series and Systematic Review of the Literature.” Genes (Basel) 15, no. 3: 346. 10.3390/GENES15030346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. van Bever Y, Groenenberg IAL, Knapen MFCM, et al. 2023. “Prenatal Ultrasound Finding of Atypical Genitalia: Counseling, Genetic Testing and Outcomes.” Prenatal Diagnosis 43, no. 2: 162–182. 10.1002/PD.6205. [DOI] [PubMed] [Google Scholar]
  22. Vlatkovic IB, Hafner T, Miskovic B, Vicic A, Poljak B, and Stipoljev F. 2014. “Prenatal Diagnosis of Sex Chromosome Aneuploidies and Disorders of Sex Development – A Retrospective Analysis of 11-Year Data.” Journal of Perinatal Medicine 42, no. 4: 529–534. 10.1515/jpm-2013-0279. [DOI] [PubMed] [Google Scholar]
  23. Weidler EM, Ochoa B, and Van Leeuwen K. 2024. “Prenatal and Postnatal Evaluation of Differences of Sex Development: A User's Guide for Clinicians and Families.” Current Opinion in Pediatrics 36, no. 5: 547–553. 10.1097/MOP.0000000000001388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Witchel SF, Rajkovic A, and Yatsenko SA. 2025. “Discrepancies Between Sex Prediction and Fetal Sex After Prenatal Noninvasive Cell-Free DNA Screening.” Journal of the Endocrine Society 9, no. 2: bvaf007. 10.1210/JENDSO/BVAF007. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary tables

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

RESOURCES